|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Penbutolol#Use in Specific Populations]] |
| {{Penbutolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| ====Teratogenic Effects====
| |
| | |
| '''Pregnancy Category C''':
| |
| | |
| Teratology studies in rats and rabbits revealed no teratogenic effects related to treatment with penbutolol at oral doses up to 200 mg/kg/day (250 times the MRHD). In rabbits, a slight increase in the intrauterine fetal mortality and a reduced 24-hour offspring survival rate were observed in the groups treated with 125 mg/kg/day (156 times the MRHD) but not in the groups treated with 0.2 and 5 mg (0.25 to 6 times the MRHD).
| |
| | |
| There are no adequate and well-controlled studies in pregnant women. levatol® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ====Nonteratogenic Effects====
| |
| | |
| In a perinatal and postnatal study in rats, the pup body weight and pup survival rate were reduced at the highest dose level of 160 mg/kg/day (200 times the MRHD).
| |
| | |
| ====Nursing Mothers====
| |
| | |
| It is not known whether levatol® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when levatol® is administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness of levatol® in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Clinical studies of levatol® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
| |
| | |
| This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LEVATOL (PENBUTOLOL SULFATE) TABLET [ACTIENT PHARMACEUTICALS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d241fc80-2c55-4dbb-bdb2-44f731afa137 | publisher = | date = | accessdate = 4 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |